Pharmaxis is a leader in mechanism-based inhibitors of amine oxidases. It has a proven ability to deliver Phase 2 trial ready compounds and an exciting pipeline of drug candidates for valuable targets. Its management team has the long standing expertise in the preclinical, early and late phase clinical trials required to secure successful drug development, as well as the strong industry relationships to deliver global transactions with major pharmaceutical partners.

Pharmaxis' research efforts are focused on discovering new drugs to treat inflammatory and fibrotic diseases such as myelofibrosis, stromal (fibrotic) cancers such as pancreatic and liver cancer, NASH, pulmonary fibrosis, chronic kidney disease, liver fibrosis, fibrotic scarring from burns and other trauma.

Product Pipeline

Amine oxidase platform

Product Candidate

Indications

Pan-LOX; PXS-5505

Myelofibrosis

Pan-LOX; PXS-5505

Liver and pancreatic cancer

LOXL-2; PXS-5382

Anti fibrotic
CKD / IPF / NASH

Pan-LOX; PXS-6302

Anti scarring;
Burns, established scars

SSAO/MAOB; PXS-4699

Anti inflammatory

Muscular Dystrophy

SSAO/MPO; PXS-5370

Anti inflammatory

Multiple indications

SSAO; PXS-4728A

Anti inflammatory

Neuro inflammation

Innovative Respiratory Device

The Pharmaxis pipeline also includes the Orbital - high payload dry powder inhaler.